Do you hesitate to start that prostaglandin?...
The Sight Outcomes Research Collaborative (SOURCE) data has given us some unexpected insight on the incidence of uveitis following the start of various glaucoma medications.
In a study involving 67,517 patients, only 0.87% developed uveitis within three months of starting treatment. And counter to what we would expect, prostaglandin analogs (PGAs) showed the lowest incidence rate at 0.32%, compared to higher rates for beta-blockers (1.95%), alpha agonists (1.63%), and carbonic anhydrase inhibitors (1.68%). After adjusting for sociodemographic factors, the use of PGAs was not associated with higher odds of developing uveitis compared to other medication classes.
These findings have significant clinical impact for glaucoma management, suggesting PGAs may actually be a safer than other options in terms of uveitis risk. We should consider these results when selecting appropriate treatments, balancing efficacy with potential adverse effects.
-JRM
Go to the article in Ophthalmology Glaucoma:
CREATE A COPE APPROVED COURSE
WITH MATERIAL YOU ALREADY HAVE!
- No Fees: Create & host your course on our powerful platform.
- Income Stream: We do the work & you earn.
- Real Partnership: Real humans.
- Utilize Existing Materials: FAAO Papers? Publish what you have!
- Share Your Expertise: Teach others to help others.
- Global Audience: Reach eager learners worldwide.
- Advance Your Career: Contribute to ophthalmic medical education.
THE FINE ART OF PATIENT MANAGEMENT ON AMAZON
Responses